Registration and prospectus / FibroBiologics, Inc. Common Stock | Tables in SEC filings

FBLG FibroBiologics, Inc. Common Stock

IPO registration (amended)

10.7	Agreement Regarding Right of First Negotiation dated January 20, 2023.	S-1/A	333-275361	10.19	November 30 2023

10.8	Sublease Agreement between United Fire & Casualty Company and FibroBiologics, Inc., effective October 5, 2022.	S-1/A	333-275361	10.6	December 4, 2023

10.9	2022 Stock Plan.	S-1/A	333-275361	10.12	November 30 2023

10.10	Form of Stock Option Notice and Grant Agreement.	S-1/A	333-275361	10.20	December 4, 2023

10.11	Employment Agreement effective from December 1, 2023, between FibroBiologics, Inc. and Pete O’Heeron.	S-1/A	333-275361	10.22	December 4, 2023

10.12	Employment Agreement effective from July 20, 2021, between FibroBiologics, LLC and Hamid Khoja.	S-1/A	333-275361	10.13	December 4, 2023

10.13	Employment Agreement effective from May 31, 2022, between FibroBiologics, Inc. and Mark Andersen.	S-1/A	333-275361	10.14	December 4, 2023

10.14*	Separation Letter Agreement, dated October 28, 2024, between FibroBiologics, Inc. and Mark Andersen

10.15*	Offer Letter, dated October 29, 2024, between FibroBiologics, Inc. and Robert E. Hoffman

10.16	Employment Agreement effective from March 1, 2024, between FibroBiologics, Inc. and Ruben Garcia.	S-1/A	333-277019	10.24	March 15, 2024

10.17	Form of Indemnification Agreement between the Registrant and each of its Directors and Executive Officers.	S-1/A	333-275361	10.15	December 4, 2023

10.18+	Master Services Agreement, effective September 19, 2024, between FibroBiologics, Inc. and Charles River Laboratories, Inc.	8-K	001-41934	10.1	September 24, 2024

10.19	Standby Equity Purchase Agreement, dated December 20, 2024, between the Registrant and YA II PN, LTD.	8-K	001-41934	10.1	December 23, 2024

10.20	Convertible Promissory Note, dated December 20, 2024, between FibroBiologics, Inc. and YA II PN, LTD.	8-K	001-41934	10.2	December 23, 2024

10.21	Registration Rights Agreement, dated December 20, 2024, between the Registrant and YA II PN, LTD.	8-K	001-41934	10.3	December 23, 2024

23.1	Consent of Norton Rose Fulbright US LLP (included in Exhibit 5.1).

23.2	Consent of WithumSmith+Brown PC.

23.3	Consent of Howard An, M.D.	S-1	333-277019	23.3	February 12, 2024

24.1*	Power of Attorney

107.1	Filing Fee Table

	As of September 30, 2024
	Actual		As Adjusted
	(unaudited, in thousands, except for share and per share amounts)
Cash and cash equivalents	$	7,827	$	31,062
Stockholders’ equity:
Preferred Stock, $0.00001 par value; 10,000,000 shares authorized, actual and as adjusted; 2,500 Series C Preferred shares authorized, issued and outstanding, actual and as adjusted		—		—
Common Stock, $0.00001 par value; 100,000,000 shares authorized, actual and as adjusted; 33,917,961 shares issued and outstanding, actual; 75,407,542 shares issued and outstanding, as adjusted		—		—
Additional paid-in capital		35,156		58,391
Accumulated deficit		(32,419)		(32,419)
Total stockholders’ equity/(deficit)	$	2,737	$	25,972
Total capitalization	$	10,469	$	33,704

	Option awards
Name	Number of securities underlying unexercised options (#) exercisable		Number of securities underlying unexercised options (#) unexercisable			Option exercise price ($)		Option expiration date
Pete O’Heeron		887,895		965,105	(1)		2.28	February 16, 2033
		—		406,339	(2)		2.36	December 26, 2034

Hamid Khoja, Ph.D.		7,500		—			3.28	September 25, 2032
		217,781		236,719	(1)		2.28	February 16, 2033
		—		176,200	(2)		2.36	December 26, 2034

Ruben A. Garcia		—		180,000	(3)		13.00	February 28, 2034
		—		176,200	(2)		2.36	December 26, 2034

	Beneficial Ownership Prior to the Offering
	Common Stock					Series C Preferred Stock					Percentage of Total Voting			Shares of Common Stock Being Registered Pursuant to this
Name and address of Beneficial Owner	Shares		%			Shares		%			Power(1)			Prospectus
5% Stockholders:
Pete O’Heeron, MSHA(2)		6,910,355		19.1	%		2,500		100	%		57.4	%		—
Golden Knight Incorporated, L.P.(3)		2,125,001		6.0	%		—		—			3.1	%		—

Named Executive Officers and Directors
Pete O’Heeron, MSHA(2)		6,910,355		19.1	%		2,500		100	%		57.4	%		—
Hamid Khoja, Ph.D. (4)		264,938		*			—		—			*			—
Ruben A. Garcia(5)		264,938		*			—		—			*			—
Robert E. Hoffman (6)		112,871		*			—		—			*			—
Victoria Niklas, M.D.(7)		112,871		*			—		—			*			—
Richard Cilento, Jr., MBA(8)		198,596		*			—		—			*			—
Stacy Coen, MBA(9)		112,871		*			—		—			*			—
Matthew Link(10)		112,871		*			—		—			*			—
Directors and Executive Officers as a Group (8 persons)(11)		7,870,373		21.3	%		2,500		100	%		58.1	%		—
Selling Stockholder:
YA II PN, Ltd.(12)		—		—			—		—			—			41,489,581
Total Number of Shares Being Registered

Named Executive Officer (2024)	401(k) Plan Matching Contributions ($)		Healthcare Benefits ($)		Relocation Expenses ($)
Pete O’Heeron		—		26,747		—
Hamid Khoja, Ph.D.		—		36,751		—
Ruben A. Garcia		15,525		7,617		18,406

Table search / Registration and prospectus / FibroBiologics, Inc. Common Stock

185 results

Top filers

Top filing types

Recent filing years